EUVIMEDEUVIMED entdecken
Crossref

Integrated UPLC-Q-Orbitrap-MS/MS, network pharmacology, and in vivo evaluation reveal bioactive constituents and mechanisms of Bushen Tongluo Decoction against idiopathic pulmonary fibrosis

Kai Li, Guirui Huang, Qiang Ye, Hongsheng Cui, Qing Miao, Peizhong Ren

Journal of Pharmaceutical and Biomedical Analysis · 2027-01 · 283 · 117764

DOI: 10.1016/j.jpba.2026.117764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2027-01. Verfasst von Kai Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Third Clinical Medical College, Beijing University of Chinese Medicine, Beijing, China; The Third Affiliated Hospital of Beijing University of Ch…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Idiopathic Pulmonary Fibrosis. Die Arbeit nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Department of Education of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The active constituents and mechanisms of Bushen Tongluo Decoction (BTD) in idiopathic pulmonary fibrosis (IPF) remain unclear. We profiled BTD constituents and serum compounds by ultra‑high‑performance liquid chromatography‑quadrupole‑Orbitrap high‑resolution tandem mass spectrometry (UPLC-Q-Orbitrap-MS/MS) and combined network pharmacology, in vivo evaluation, molecular docking, molecular dynamics (MD) simulation, and surface plasmon resonance (SPR) analysis to identify candidate bioactive compounds and associated mechanisms.We identified 614 constituents in BTD and 100 serum compounds, including 50 prototype compounds and 50 metabolites; 32 met Level 1 identification criteria. Network pharmacology identified 171 shared targets and prioritized transforming growth factor‑beta (TGF-β)- and mitogen‑activated protein kinase (MAPK)-related pathways. BTD reduced histopathological injury, collagen accumulation, and α‑smooth muscle actin (α‑SMA) and fibronectin 1 (FN1) expression, with stronger effects at the higher dose. Treatment was associated with changes in TGF-β1, Smad2/3, extracellular signal‑regulated kinase (ERK), and their phosphorylated forms. Ellagic acid showed the most favorable predicted binding energy at the latency-associated peptide (LAP)- growth factor (GF) interface of TGF-β1. MD analyses supported relative complex stability and yielded an estimated binding free energy of -59.43 ± 4.79 kJ/mol. SPR analysis detected binding between ellagic acid and TGF-β1, yielding a KD of 3.63 × 10⁻⁶ M. These findings indicate that BTD attenuated experimental pulmonary fibrosis and nominate ellagic acid as a candidate active constituent, and support the involvement of TGF-β1/Smads/ERK-related signaling in its effects on experimental pulmonary fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalIdiopathic Pulmonary FibrosisAnimalsTandem Mass SpectrometryChromatography, High Pressure LiquidNetwork PharmacologyMaleMolecular Docking SimulationTransforming Growth Factor beta1Molecular Dynamics SimulationMiceBleomycinDisease Models, AnimalLungHumansSurface Plasmon ResonanceRatsMice, Inbred C57BLSignal Transduction

Stichwörter der Autor:innen

Bushen Tongluo DecoctionEllagic acidIdiopathic pulmonary fibrosisNetwork pharmacologyTGF-β1/Smads/ERK signalingUPLC-Q-Orbitrap-MS/MS

Substanzen

Drugs, Chinese HerbalTransforming Growth Factor beta1Bleomycin

Autor:innen und Institutionen

  • The Third Clinical Medical College, Beijing University of Chinese Medicine, Beijing, China; The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.
  • Guangzhou University of Chinese Medicine Affiliated Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Guangzhou, China.
  • The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
  • The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China. Electronic address: Hshcui@sina.com.
  • Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: miaoqing55@aliyun.com.
  • The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: pzhren@zcmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Department of Education of Zhejiang Province

Zitieren

APA

Li, K., Huang, G., Ye, Q., Cui, H., Miao, Q., & Ren, P. (2027). Integrated UPLC-Q-Orbitrap-MS/MS, network pharmacology, and in vivo evaluation reveal bioactive constituents and mechanisms of Bushen Tongluo Decoction against idiopathic pulmonary fibrosis. Journal of Pharmaceutical and Biomedical Analysis, 283, 117764. https://doi.org/10.1016/j.jpba.2026.117764

Vancouver

Li K, Huang G, Ye Q, Cui H, Miao Q, Ren P. Integrated UPLC-Q-Orbitrap-MS/MS, network pharmacology, and in vivo evaluation reveal bioactive constituents and mechanisms of Bushen Tongluo Decoction against idiopathic pulmonary fibrosis. Journal of Pharmaceutical and Biomedical Analysis. 2027;283:117764. doi:10.1016/j.jpba.2026.117764

BibTeX
@article{Li2027,
  author = {Li, Kai and Huang, Guirui and Ye, Qiang and Cui, Hongsheng and Miao, Qing and Ren, Peizhong},
  title = {Integrated UPLC-Q-Orbitrap-MS/MS, network pharmacology, and in vivo evaluation reveal bioactive constituents and mechanisms of Bushen Tongluo Decoction against idiopathic pulmonary fibrosis},
  journal = {Journal of Pharmaceutical and Biomedical Analysis},
  year = {2027},
  volume = {283},
  pages = {117764},
  doi = {10.1016/j.jpba.2026.117764}
}
Kostenlos starten →